SCHEMBL21434002

SCHEMBL21434002

Fc1cc(-c2cc(N3CCC(c4c[nH]cn4)CC3)ccn2)ccc1OC(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GRM2 Q14416 3/20 0.35
▸ FAAH O00519 1/20 0.34
▸ SYK P43405 1/20 0.34
▸ NTRK1 P04629 1/20 0.34
▸ HRH4 Q9H3N8 2/20 0.34
▸ TRPA1 O75762 2/20 0.34
▸ LCAT P04180 1/20 0.34
▸ TRPV4 Q9HBA0 1/20 0.34
▸ FFAR4 Q5NUL3 1/20 0.33
▸ PHF8 Q9UPP1 2/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ RPS6KB1 P23443 3/20 0.32
▸ KDM2B Q8NHM5 1/20 0.32
▸ AKT1 P31749 2/20 0.32
▸ TTK P33981 1/20 0.32
▸ PLK1 P53350 1/20 0.32
▸ AKT2 P31751 1/20 0.32
▸ AKT3 Q9Y243 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21434063 0.85 RPS6KB1 (0.43) FAAHHRH4TRPA1RPS6KB1AKT1
SCHEMBL21433999 0.84 ROCK2 (0.37) GRM2FAAHSYKLCATPHF8
SCHEMBL21434015 0.84 ABL1 (0.42) GRM2FAAHNTRK1TRPA1TRPV4
SCHEMBL21433926 0.83 HTR2B (0.41) GRM2FAAHSYKNTRK1LCAT
SCHEMBL21434017 0.83 LCAT (0.35) GRM2FAAHSYKNTRK1TRPA1
SCHEMBL21452938 0.83 MAPK1 (0.39) GRM2FAAHSYKNTRK1HRH4
SCHEMBL21453054 0.81 NTRK1 (0.36) GRM2FAAHSYKNTRK1HRH4
SCHEMBL21434003 0.81 FAAH (0.41) GRM2FAAHSYKHRH4TRPA1
SCHEMBL21433991 0.79 SCN9A (0.46) NTRK1FFAR4CHRM2
SCHEMBL21453056 0.77 PDE2A (0.38) GRM2FAAHSYKHRH4TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008302-B2 Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2021-05-18 — — US claimed
EP-3774732-A2 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2021-02-17 — — EP claimed
WO-2019193516-A2 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-10 — — WO claimed
US-20190308950-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-10 — — US claimed
US-20210340121-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-11-04 — — US disclosed
US-20210340121-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-11-04 — — US disclosed
US-11008302-B2 Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2021-05-18 — — US disclosed
US-11008302-B2 Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2021-05-18 — — US disclosed
EP-3774732-A2 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2021-02-17 — — EP disclosed
WO-2019193516-A2 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-10 — — WO disclosed
WO-2019193516-A2 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-10 — — WO disclosed
US-20190308950-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-10 — — US disclosed
US-20190308950-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190308950-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN3B GRM2 9/4885FAAH 3070/4885SYK 923/4885
US-20210340121-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN3B GRM2 9/4885FAAH 3070/4885SYK 923/4885
US-11008302-B2 Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators GRIN2B, GRIN2A, GRIN3B GRM2 8/4885FAAH 2955/4885SYK 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback